No Data
No Data
No Data
Dynavax Reports First Participant Dosed in Shingles Vaccine Trial
Dynavax Technologies (DVAX) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster
Arthrosi Announces First Patient Dosed in Pivotal Phase 3 REDUCE 2 Trial of Lead Compound AR882
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation...
Express News | Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)
Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With A Potential New Drug Application Submission In 2026
Quince Therapeutics Has Dosed The First Patient In Phase 3 NEAT Trial To Evaluate Neurological Effects Of EryDex In Patients With Ataxia-telangiectasia, Topline Results Are Expected In 2H Of 2025 With
Express News | Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia
Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
Ideaya Biosciences Has Dosed Its First Patient In Phase 1 Trial Of IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan-hziy), In Patients With MTAP-deletion Bladder Cancer
No Data